MedTrace Logo

Varenicline (Chantix™) for the Treatment of Alcohol Dependence

NCT00705523 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of varenicline (Chantix™) for the treatment of alcohol dependence.

Conditions

  • Alcoholism

Interventions

DRUG

varenicline

1.0 mg BID for 12 weeks

DRUG

placebo

BID 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Jennifer G Plebani, PhD · University of Pennsylvania, Treatment Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-03-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705523 on ClinicalTrials.gov